Opportunity Information: Apply for RFA HG 25 012
This funding opportunity is a limited-competition NIH Notice of Funding Opportunity (NOFO) for the next phase of the Electronic Medical Records and Genomics (eMERGE) program, focused specifically on outcomes. The program is titled "Outcomes of Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network - Clinical Sites" and uses the U01 cooperative agreement mechanism, meaning NIH will have substantial involvement in how the project is carried out compared with a typical investigator-initiated grant. It is also labeled "Clinical Trial Required," which signals that applicants are expected to conduct activities that meet NIH's definition of a clinical trial, such as prospective assignment or evaluation of interventions related to genomic risk assessment and management in real-world clinical settings.
The core purpose of the NOFO is to continue and expand follow-up for patients who previously received genomically informed risk assessment (GIRA) and related management recommendations through earlier eMERGE clinical site awards. The key emphasis is on collecting longer-term outcome data to understand what happens after genomic information is delivered and acted on in clinical care. NIH indicates that the eMERGE Network will extend through April 2030, with follow-up and outcome-data collection on roughly 25,000 patients. In practice, this is about moving beyond initial implementation and looking carefully at downstream clinical results, care processes, and the real-world impact of genomics integrated into electronic medical records.
Eligibility is tightly restricted. This is not an open competition; only organizations that were funded under the earlier eMERGE clinical site announcements RFA-HG-19-013 and RFA-HG-19-014 may apply. Applications will still go through standard NIH peer review, and only those deemed scientifically and operationally strong will be considered for funding, but the applicant pool is intentionally limited to existing, previously funded eMERGE clinical sites.
Several restrictions relate to foreign involvement. Non-U.S. entities (foreign organizations) cannot apply, and non-U.S. components of U.S. organizations are also not eligible to apply. The NOFO notes that "foreign components" as defined in the NIH Grants Policy Statement are allowed, which generally refers to certain project elements conducted outside the U.S. under specific NIH rules and disclosures. At the same time, NIH policy effective May 1, 2025 adds a major constraint: NIH will not issue awards that involve foreign subawards or subcontracts unless the application is submitted to a NOFO explicitly designed for funded international collaborations. As a result, any application to this NOFO that includes foreign subawards/subcontracts will be considered noncompliant and will not be funded. The policy does not forbid all international interaction; it still allows unfunded collaborations, foreign components where permissible, paying foreign consultants in allowable ways, or purchasing specialized equipment or supplies from foreign vendors. The main line NIH draws here is against sending grant funds to foreign institutions through subawards or subcontracts under this particular NOFO.
From an administrative and funding standpoint, the opportunity is issued by the National Institutes of Health (NIH) under CFDA (Assistance Listing) 93.172, and it is categorized as a discretionary health-related program. The opportunity number is RFA-HG-25-012, and the funding instrument is a cooperative agreement (U01). The original application closing date is January 30, 2026. NIH anticipates making about 10 awards, and the listed award ceiling is $330,000 (as presented in the source information), indicating an upper bound on the amount NIH expects to provide per award under the terms described.
Overall, the NOFO is essentially a continuation-and-outcomes phase for established eMERGE clinical sites: keep the network operating, continue following the previously enrolled cohort, and systematically collect outcome data through 2030 to determine the longer-term clinical and implementation effects of embedding genomic risk assessment and management into routine care via electronic medical records, all within a structured NIH-led cooperative agreement framework.Apply for RFA HG 25 012
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition: Outcomes of Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network - Clinical Sites (U01, Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172.
- This funding opportunity was created on 2025-12-23.
- Applicants must submit their applications by 2026-01-30. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $330,000.00 in funding.
- The number of recipients for this funding is limited to 10 candidate(s).
- Eligible applicants include: Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This is a limited-competition NIH Notice of Funding Opportunity (NOFO) for the next phase of the Electronic Medical Records and Genomics (eMERGE) program focused on outcomes. The program is titled "Outcomes of Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network - Clinical Sites."
What is the NOFO number for this opportunity?
The opportunity number is RFA-HG-25-012.
Which NIH funding mechanism is being used?
The award mechanism is a U01 cooperative agreement, which means NIH is expected to have substantial involvement in how the project is carried out compared with a typical investigator-initiated grant.
Is a clinical trial required?
Yes. The opportunity is labeled "Clinical Trial Required," indicating that funded activities are expected to meet NIH's definition of a clinical trial (for example, prospective assignment or evaluation of interventions related to genomic risk assessment and management in real-world clinical settings).
What is the main purpose of this eMERGE outcomes phase?
The core purpose is to continue and expand follow-up for patients who previously received genomically informed risk assessment (GIRA) and related management recommendations through earlier eMERGE clinical site awards, with a key emphasis on collecting longer-term outcome data.
What kinds of outcomes or data are being emphasized?
The emphasis is on longer-term outcome data to understand what happens after genomic information is delivered and acted on in clinical care, including downstream clinical results, care processes, and the real-world impact of integrating genomics into electronic medical records.
Is this an open competition?
No. This is a limited-competition NOFO with tightly restricted eligibility.
Who is eligible to apply?
Only organizations that were funded under the earlier eMERGE clinical site announcements RFA-HG-19-013 and RFA-HG-19-014 may apply.
Will applications still be peer reviewed?
Yes. Applications will go through standard NIH peer review, and only those deemed scientifically and operationally strong will be considered for funding.
How long is the eMERGE Network expected to run?
NIH indicates the eMERGE Network will extend through April 2030.
How many patients are expected to be included in follow-up and outcomes collection?
NIH describes follow-up and outcome-data collection on roughly 25,000 patients.
Is this opportunity focused on new patient enrollment or follow-up of previously assessed patients?
Based on the description provided, the focus is on continuing and expanding follow-up for patients who previously received genomically informed risk assessment (GIRA) and management recommendations through earlier eMERGE clinical site awards.
Are foreign organizations eligible to apply?
No. Non-U.S. entities (foreign organizations) cannot apply.
Are non-U.S. components of U.S. organizations eligible to apply?
No. Non-U.S. components of U.S. organizations are not eligible to apply.
Are foreign components allowed at all under this NOFO?
The NOFO notes that "foreign components" (as defined in the NIH Grants Policy Statement) are allowed, generally referring to certain project elements conducted outside the U.S. under specific NIH rules and disclosures.
Can an application include foreign subawards or foreign subcontracts?
No. NIH policy effective May 1, 2025 states NIH will not issue awards that involve foreign subawards or subcontracts unless the application is submitted to a NOFO explicitly designed for funded international collaborations. Under this NOFO, applications that include foreign subawards/subcontracts are considered noncompliant and will not be funded.
Does the policy prohibit all international collaboration?
No. The information provided indicates the policy does not forbid all international interaction. It allows, for example, unfunded collaborations, permissible foreign components (with required disclosures and compliance), paying foreign consultants in allowable ways, or purchasing specialized equipment or supplies from foreign vendors. The key restriction described here is against sending grant funds to foreign institutions through subawards or subcontracts under this NOFO.
Which federal program listing is associated with this opportunity?
The opportunity is issued under CFDA (Assistance Listing) 93.172.
What agency is offering this funding opportunity?
The offering agency is the National Institutes of Health (NIH).
How many awards does NIH anticipate making?
NIH anticipates making about 10 awards.
What is the maximum award amount (award ceiling) listed?
The listed award ceiling is $330,000 (as presented in the source information), indicating an upper bound on the amount NIH expects to provide per award under the terms described.
What is the application deadline?
The original application closing date is January 30, 2026.
What does "substantial NIH involvement" mean in this context?
Because this is a U01 cooperative agreement, NIH is expected to be substantially involved in the project, meaning the work is carried out within a structured NIH-led cooperative agreement framework rather than being entirely investigator-directed as in typical investigator-initiated grants.
What is the overall goal of the funded work through 2030?
The overall goal is to keep the network operating, continue following the previously enrolled cohort, and systematically collect outcome data through 2030 to determine the longer-term clinical and implementation effects of embedding genomic risk assessment and management into routine care via electronic medical records.
Browse more opportunities from the same category: Health
Next opportunity: Special Research Grants Program for Aquaculture Research
Previous opportunity: Deployed Warfighter Protection (DWFP) Program for the Protection of Deployed Military Personnel from Threats Posed by Arthropod Disease Vectors
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HG 25 012
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HG 25 012) also looked into and applied for these:
| Funding Opportunity |
|---|
| Informatics, Coordination and Service Center for the Mutant Mouse Resource and Research Centers (U42 Clinical Trial Not Allowed) Apply for RFA OD 25 012 Funding Number: RFA OD 25 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Animal and Biological Material Resource Centers (P40 Clinical Trial Not Allowed) Apply for RFA OD 25 011 Funding Number: RFA OD 25 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Resource-Related Research Projects for Development of Models and Related Materials for Studying Human Health and Diseases (R24 Clinical Trials Not Allowed) Apply for RFA OD 25 010 Funding Number: RFA OD 25 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional) Apply for PAR 26 116 Funding Number: PAR 26 116 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NIGMS Institutional Biomedical Undergraduate Research Training (BURT) Program (T34) Apply for PAR 26 033 Funding Number: PAR 26 033 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Maximizing Investigators' Research Award (MIRA) (R35 - Clinical Trial Optional) Apply for PAR 26 121 Funding Number: PAR 26 121 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) Apply for PA 26 001 Funding Number: PA 26 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Extension of the World Trade Center Health Registry (U50) Apply for RFA OH 26 016 Funding Number: RFA OH 26 016 Agency: Centers for Disease Control and Prevention - ERA Category: Health Funding Amount: $9,480,000 |
| Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional) Apply for PAR 25 444 Funding Number: PAR 25 444 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cancer Intervention and Surveillance Modeling Network (CISNET) (U01 Clinical Trial Not Allowed) Apply for RFA CA 25 032 Funding Number: RFA CA 25 032 Agency: National Institutes of Health Category: Health Funding Amount: $1,240,000 |
| Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies (R01 - Clinical Trial Not Allowed) Apply for RFA DK 26 306 Funding Number: RFA DK 26 306 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Drug-Free Communities (DFC) Support Program - New (Year 1 Recompete) Apply for CDC RFA CE 26 0220 Funding Number: CDC RFA CE 26 0220 Agency: Centers for Disease Control - NCIPC Category: Health Funding Amount: $125,000 |
| Drug-Free Communities (DFC) Support Program - (Year 6 - FY25 Cohort) Apply for CDC RFA CE 26 0208 Funding Number: CDC RFA CE 26 0208 Agency: Centers for Disease Control - NCIPC Category: Health Funding Amount: $125,000 |
| Fiscal Year (FY) 2026 National Technical Assistance Programs (NTAP) Cooperative Agreements Apply for HRSA 26 009 Funding Number: HRSA 26 009 Agency: Health Resources and Services Administration Category: Health Funding Amount: $8,000,000 |
| Single Source: Outcomes of Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network - Coordinating Center (U01 Clinical Trial Required) Apply for RFA HG 26 008 Funding Number: RFA HG 26 008 Agency: National Institutes of Health Category: Health Funding Amount: $687,000 |
| Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed) Apply for RFA RM 26 017 Funding Number: RFA RM 26 017 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional) Apply for PA 26 002 Funding Number: PA 26 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| FY2026 Cooperative Agreement for 988 Suicide & Crisis Lifeline Administrator Apply for FG 26 001 Funding Number: FG 26 001 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $231,482,876 |
| Service Area Competition - Additional Area 1 Apply for HRSA 26 007 Funding Number: HRSA 26 007 Agency: Health Resources and Services Administration Category: Health Funding Amount: $1,565,269 |
| The NINDS Human Biospecimen and Data Repository (U24 - Clinical Trial Not Allowed) Apply for RFA NS 26 010 Funding Number: RFA NS 26 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HG 25 012", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.